Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Unknown 10Terminated 4Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Other solid neoplasm 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Triple Negative Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × tesetaxel × Clear all
NCT03326674 2021-07-30

CONTESSA

Odonate Therapeutics, Inc.

Phase 3 Terminated
685 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03858972 2021-07-30

CONTESSA 2

Odonate Therapeutics, Inc.

Phase 2 Terminated
152 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Odonate Therapeutics, Inc.

Phase 2 Terminated
294 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04312282 2021-07-28

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

Odonate Therapeutics, Inc.

Phase 1 Terminated
93 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡